IL249016B - Alkyl history of 1-oxa-9,4-diazaspiro-undecane compounds with multimodal analgesic activity - Google Patents

Alkyl history of 1-oxa-9,4-diazaspiro-undecane compounds with multimodal analgesic activity

Info

Publication number
IL249016B
IL249016B IL249016A IL24901616A IL249016B IL 249016 B IL249016 B IL 249016B IL 249016 A IL249016 A IL 249016A IL 24901616 A IL24901616 A IL 24901616A IL 249016 B IL249016 B IL 249016B
Authority
IL
Israel
Prior art keywords
oxa
activity against
alkyl derivatives
against pain
multimodal activity
Prior art date
Application number
IL249016A
Other languages
English (en)
Hebrew (he)
Other versions
IL249016A0 (en
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of IL249016A0 publication Critical patent/IL249016A0/en
Publication of IL249016B publication Critical patent/IL249016B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL249016A 2014-06-02 2016-11-16 Alkyl history of 1-oxa-9,4-diazaspiro-undecane compounds with multimodal analgesic activity IL249016B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382209 2014-06-02
PCT/EP2015/001115 WO2015185209A1 (en) 2014-06-02 2015-06-02 Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Publications (2)

Publication Number Publication Date
IL249016A0 IL249016A0 (en) 2017-01-31
IL249016B true IL249016B (en) 2020-05-31

Family

ID=50972618

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249016A IL249016B (en) 2014-06-02 2016-11-16 Alkyl history of 1-oxa-9,4-diazaspiro-undecane compounds with multimodal analgesic activity

Country Status (21)

Country Link
US (2) US10246465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3149006B1 (cg-RX-API-DMAC7.html)
JP (1) JP6611736B2 (cg-RX-API-DMAC7.html)
KR (1) KR102468874B1 (cg-RX-API-DMAC7.html)
CN (1) CN106414457B (cg-RX-API-DMAC7.html)
AR (1) AR100715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015271248B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027825B1 (cg-RX-API-DMAC7.html)
CA (1) CA2949573C (cg-RX-API-DMAC7.html)
IL (1) IL249016B (cg-RX-API-DMAC7.html)
MX (1) MX2016015760A (cg-RX-API-DMAC7.html)
MY (1) MY177365A (cg-RX-API-DMAC7.html)
NZ (1) NZ726476A (cg-RX-API-DMAC7.html)
PH (1) PH12016502307B1 (cg-RX-API-DMAC7.html)
RU (1) RU2720406C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201810660QA (cg-RX-API-DMAC7.html)
TN (1) TN2016000509A1 (cg-RX-API-DMAC7.html)
TW (1) TWI685497B (cg-RX-API-DMAC7.html)
UA (1) UA124049C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015185209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608079B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
AR106444A1 (es) * 2015-10-23 2018-01-17 Esteve Labor Dr Compuestos oxaazaespíricos con actividad contra el dolor
RS59956B1 (sr) 2015-10-23 2020-03-31 Esteve Pharmaceuticals Sa Oksa-diazaspiro jedinjenja koja imaju aktivnost protiv bola
TN2018000122A1 (en) * 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US10807970B2 (en) * 2016-05-20 2020-10-20 Esteve Pharmaceuticals, S.A. Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
FI3697795T3 (fi) * 2017-10-17 2024-02-23 Acondicionamiento Tarrasense (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja
WO2019158634A1 (en) 2018-02-16 2019-08-22 Esteve Pharmaceuticals, S.A. Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
WO2019180188A1 (en) * 2018-03-23 2019-09-26 Esteve Pharmaceuticals, S.A. Aminopropoxyphenyl and benzyl 1-oxa-4,9-diazaspiroundecane derivatives having multimodal activity against pain
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2021018824A1 (en) 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2133610B1 (cg-RX-API-DMAC7.html) * 1971-04-15 1975-10-31 Sumitomo Chemical Co
US4332804A (en) * 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030061A1 (de) 2005-06-27 2006-12-28 Behr Gmbh & Co. Kg Klimagerät
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
CN102083839B (zh) 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 化合物
US8828996B2 (en) * 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物

Also Published As

Publication number Publication date
MX2016015760A (es) 2017-04-10
CN106414457A (zh) 2017-02-15
PH12016502307B1 (en) 2020-02-28
BR112016027825A2 (cg-RX-API-DMAC7.html) 2017-08-22
RU2016150518A3 (cg-RX-API-DMAC7.html) 2019-01-21
IL249016A0 (en) 2017-01-31
WO2015185209A1 (en) 2015-12-10
EP3149006B1 (en) 2020-09-09
UA124049C2 (uk) 2021-07-14
US10246465B2 (en) 2019-04-02
CA2949573C (en) 2023-07-18
AR100715A1 (es) 2016-10-26
KR20170012444A (ko) 2017-02-02
JP2017516818A (ja) 2017-06-22
SG10201810660QA (en) 2018-12-28
RU2720406C2 (ru) 2020-04-29
US20170313723A1 (en) 2017-11-02
KR102468874B1 (ko) 2022-11-17
TN2016000509A1 (en) 2018-04-04
ZA201608079B (en) 2017-09-27
AU2015271248A1 (en) 2016-12-15
TWI685497B (zh) 2020-02-21
NZ726476A (en) 2023-07-28
JP6611736B2 (ja) 2019-11-27
MY177365A (en) 2020-09-14
EP3149006A1 (en) 2017-04-05
CN106414457B (zh) 2020-04-17
AU2015271248B2 (en) 2019-10-31
RU2016150518A (ru) 2018-07-16
US20190177337A1 (en) 2019-06-13
PH12016502307A1 (en) 2017-02-13
SG11201609632UA (en) 2016-12-29
BR112016027825B1 (pt) 2023-03-28
CA2949573A1 (en) 2015-12-10
TW201617352A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
IL275344B1 (en) 4-azaindole compounds
IL275365A (en) 6-Azaindole compounds
ZA201608079B (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
PT3149007T (pt) Derivados de alquilo e arilo de compostos de 1-oxa-4,9-diazaespiro undecano tendo atividade multimodal contra a dor
ZA201607736B (en) Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP2968311A4 (en) OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
IL247289A0 (en) Use of 3-isoxolidinone compounds as selective herbicides
PT3149005T (pt) Derivados de amida de compostos de 1-oxa-4,9-diazaespiro undecano tendo atividade multimodal contra a dor
CL2016003145A1 (es) Compuestos de [1,2,4]triazol sustituido
IL247155A0 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
IL251164A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3197275A4 (en) 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
PL2949650T3 (pl) Syntetyczny sposób otrzymywania 1,2-benzoizotiazolin-3-onu
IL267145B (en) Spiropyridine derivatives
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
IL251166A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees